Pathogenetic rationale for prescribing menopausal hormone therapy for systemic sclerosis
https://doi.org/10.47360/1995-4484-2022-538-545
Abstract
Systemic scleroderma (SS) is characterized by dysregulation of the innate and adaptive immune systems, vasculopathy, and generalized fibrosis. As with most autoimmune diseases, women predominate among patients, who get sick 3–14 times more often than men. It is assumed that gender differences and modulation of sex hormones are essential in the pathogenesis of SS. Estrogens are able to influence the immune response, have a vasodilating effect and stimulate the synthesis of collagen in the skin. The development of SS leads to a significant decrease in the quality of life, psychological disorders associated with changes in appearance, as well as the need for lifelong medication with the frequent development of side effects. Age-related estrogen deficiency associated with the onset of menopause is accompanied by a decrease in the quality of life and, in some cases, a change in the clinical manifestations of somatic diseases. This review considers the impact of menopause and menopausal hormone therapy (MHT) on the course and clinical manifestations of systemic scleroderma. It is noted that SS in some cases is accompanied by an early onset of menopause. The use of MHT is not associated with the progression of cutaneous fibrosis, and may also improve the vascular manifestations of SS.
About the Authors
T. S. Panevin
V.A. Nasonova Research Institute of Rheumatology
Russian Federation
Russian Federation
115522, Moscow, Kashirskoye Highway, 34A
L. P. Ananyeva
V.A. Nasonova Research Institute of Rheumatology
Russian Federation
Russian Federation
115522, Moscow, Kashirskoye Highway, 34A
References
1. Gabrielli A, Avvedimento EV, Krieg T. Scleroderma. N Engl J Med. 2009;360(19):1989-2003. doi: 10.1056/NEJMra0806188
2. Marie I, Gehanno JF. Environmental risk factors of systemic sclerosis. Semin Immunopathol. 2015;37(5):463-473. doi: 10.1007/ s00281-015-0507-3
3. Elhai M, Avouac J, Walker UA, Matucci-Cerinic M, Riemekasten G, Airò P, et al.; EUSTAR co-authors. A gender gap in primary and secondary heart dysfunctions in systemic sclerosis: A EUSTAR prospective study. Ann Rheum Dis. 2016;75(1):163-169. doi: 10.1136/annrheumdis-2014-206386
4. Ruzehaji N, Avouac J, Elhai M, Frechet M, Frantz C, Ruiz B, et al. Combined effect of genetic background and gender in a mouse model of bleomycin-induced skin fibrosis. Arthritis Res Ther. 2015;17(1):145. doi: 10.1186/s13075-015-0659-5
5. D’Amico F, Skarmoutsou E, Mazzarino MC. The sex bias in systemic sclerosis: On the possible mechanisms underlying the female disease preponderance. Clin Rev Allergy Immunol. 2014;47(3): 334-343. doi: 10.1007/s12016-013-8392-9
6. Ciaffi J, van Leeuwen NM, Schoones JW, Huizinga TWJ, de Vries-Bouwstra JK. Sex hormones and sex hormone-targeting therapies in systemic sclerosis: A systematic literature review. Semin Arthritis Rheum. 2020;50(1):140-148. doi: 10.1016/ j.semarthrit.2019.07.007
7. Ascenzi P, Bocedi A, Marino M. Structure-function relationship of estrogen receptor alpha and beta: Impact on human health. Mol Aspects Med. 2006;27(4):299-402. doi: 10.1016/j.mam.2006.07.001
8. Giovannetti A, Maselli A, Colasanti T, Rosato E, Salsano F, Pisarri S, et al. Autoantibodies to estrogen receptor α in systemic sclerosis (SSc) as pathogenetic determinants and markers of progression. PLoS One. 2013;8(9):e74332. doi: 10.1371/journal.pone. 0074332
9. Campochiaro C, Host LV, Ong VH, Denton CP. Development of systemic sclerosis in transgender females: a case series and review of the literature. Clin Exp Rheumatol. 2018;113(4 Suppl 36):50-52.
10. Kauffman RP, Castracane VD. Premature ovarian failure associated with autoimmune polyglandular syndrome: Pathophysiological mechanisms and future fertility. J Womens Health (Larchmt). 2003;12(5):513-520. doi: 10.1089/154099903766651649
11. Mignot MH, Schoemaker J, Kleingeld M, Rao BR, Drexhage HA. Premature ovarian failure. I: The association with autoimmunity. Eur J Obstet Gynecol Reprod Biol. 1989;30(1):59-66. doi: 10.1016/0028-2243(89)90094-4
12. Sampaio-Barros PD, Samara AM, Marques Neto JF. Gynaecologic history in systemic sclerosis. Clin Rheumatol. 2000;19(3): 184-187. doi: 10.1007/s100670050152
13. La Montagna G, Vatti M, Valentini G, Tirri G. Osteopenia in systemic sclerosis. Evidence of a participating role of earlier menopause. Clin Rheumatol. 1991;10(1):18-22. doi: 10.1007/BF02208027
14. Bhadauria S, Moser DK, Clements PJ, Singh RR, Lachenbruch PA, Pitkin RM, et al. Genital tract abnormalities and female sexual function impairment in systemic sclerosis. Am J Obstet Gynecol. 1995;172(2 Pt 1):580-587. doi: 10.1016/0002- 9378(95)90576-6
15. Perković D, Martinović Kaliterna D, Jurišić Z, Lalovac M, Radić M. Androgens in post-menopausal patients with systemic sclerosis. Rheumatology (Oxford). 2015;54(4):744-746. doi: 10.1093/ rheumatology/keu432
16. Russian Society of Obstetricians and Gynaecologists. Menopause and menopausal condition in a woman. Clinical guidelines. Moscow;2021 (In Russ.)
17. Madyanov IV, Madyanova TS. Menopausal hormonal therapy: What a physician must know? Lechaschi vrach. 2017;3:44-47 (In Russ.).
18. Rossouw JE, Anderson GL, Prentice RL, LaCroix AZ, Kooperberg C, Stefanick ML, et al.; Writing Group for the Women’s Health Initiative Investigators. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: Principal results from the Women’s Health Initiative randomized controlled trial. JAMA. 2002;288(3):321-333. doi: 10.1001/jama.288.3.321
19. Balan VE, Andreeva EN, Yureneva SV, Tkacheva ON, Ilyukhin EA. Risk and benefits of menopausal hormonal therapy. Obstetrics and Gynecology. 2020;3:33-41 (In Russ.). doi: 10.18565/aig.2020.3.33-41
20. Kryukov EV, Panevin TS. Antithrombogenic vessel wall activity in women with climacteric myocardiodystrophy during the period of peri- and postmenopause. Bulletin of Pirogov National Medical & Surgical Center. 2020;15(2):67-70 (In Russ.). doi: 10.25881/BPNMSC.2020.26.26.010
21. Kryukov EV, Panevin TS, Popova LV. Age-related changes in the hemostasis system. Clinical Medicine (Russian Journal). 2020; 98(1):9-12 (In Russ.). doi: 10.34651/0023-2149-2020-98-1-9-12
22. Kryukov EV, Popova LV, Vasiliev SV, Panevin TS, Panevina AS, Stromskaya UA, et al. Ultra-low dose estradiol plus dydrogesterone: A role in prevention of the development and progression of atherosclerosis. Bulletin of the Russian Military Medical Academy. 2021;23(1):9-14 (In Russ.). doi: 10.17816/ brmma63562
23. Kowal-Bielecka O, Fransen J, Avouac J, Becker M, Kulak A, Allanore Y, et al.; EUSTAR Coauthors. Update of EULAR recommendations for the treatment of systemic sclerosis. Ann Rheum Dis. 2017;76(8):1327-1339. doi: 10.1136/annrheumdis-2016-209909
24. Aida-Yasuoka K, Peoples C, Yasuoka H, Hershberger P, Thiel K, Cauley JA, et al. Estradiol promotes the development of a fibrotic phenotype and is increased in the serum of patients with systemic sclerosis. Arthritis Res Ther. 2013;15(1):R10. doi: 10.1186/ar4140
25. Kashnikova LN, Grozdova MD, Panasiuk AF. Significance of estradiol in the development of fibrosis in systemic scleroderma (bases of sexual predisposition to the disease). Bulletin of Experimental Biology and Medicine. 1991;111(4):365-367 (In Russ.).
26. Soldano S, Montagna P, Brizzolara R, Sulli A, Parodi A, Seriolo B, et al. Effects of estrogens on extracellular matrix synthesis in cultures of human normal and scleroderma skin fibroblasts. Ann N Y Acad Sci. 2010;1193:25-29. doi: 10.1111/j.1749-6632.2009.05296.x
27. Avouac J, Pezet S, Gonzalez V, Baudoin L, Cauvet A, Ruiz B, et al. Estrogens counteract the profibrotic effects of TGF-β and their inhibition exacerbates experimental dermal fibrosis. J Invest Dermatol. 2020;140(3):593-601.e7. doi: 10.1016/ j.jid.2019.07.719
28. Hall G, Phillips TJ. Estrogen and skin: the effects of estrogen, menopause, and hormone replacement therapy on the skin. J Am Acad Dermatol. 2005;53(4):555-568. doi: 10.1016/ j.jaad.2004.08.039
29. Brincat M, Kabalan S, Studd JW, Moniz CF, de Trafford J, Montgomery J. A study of the decrease of skin collagen content, skin thickness, and bone mass in the postmenopausal woman. Obstet Gynecol. 1987;70(6):840-845.
30. Maheux R, Naud F, Rioux M, Grenier R, Lemay A, Guy J, et al. A randomized, double-blind, placebo-controlled study on the effect of conjugated estrogens on skin thickness. Am J Obstet Gynecol. 1994;170(2):642-649. doi: 10.1016/s0002-9378(94)70242-x
31. Vinet É, Bernatsky S, Hudson M, Pineau CA, Baron M; Canadian Scleroderma Research Group. Effect of menopause on the modified Rodnan skin score in systemic sclerosis. Arthritis Res Ther. 2014;16(3):R130. doi: 10.1186/ar4587
32. Medsger TA Jr. Natural history of systemic sclerosis and the assessment of disease activity, severity, functional status, and psychologic well-being. Rheum Dis Clin North Am. 2003;29(2):255-273. doi: 10.1016/s0889-857x(03)00023-1
33. Omair MA, Pagnoux C, McDonald-Blumer H, Johnson SR. Low bone density in systemic sclerosis. A systematic review. J Rheumatol. 2013;40(11):1881-1890. doi: 10.3899/jrheum.130032
34. Dovio A, Data V, Carignola R, Calzolari G, Vitetta R, Ventura M, et al. Circulating osteoprotegerin and soluble RANK ligand in systemic sclerosis. J Rheumatol. 2008;35(11):2206-2213. doi: 10.3899/ jrheum.080192
35. Kilic G, Kilic E, Akgul O, Ozgocmen S. Increased risk for bone loss in women with systemic sclerosis: A comparative study with rheumatoid arthritis. Int J Rheum Dis. 2016;19(4):405-411. doi: 10.1111/1756-185X.12242
36. Dobrovolskaya OV, Demin NV, Smirnov AV, Garzanova LA, Toroptsova NV, Alekperov RT. Bone mineral density in patients with systemic scleroderma. Modern Rheumatology Journal. 2019;13(1):58-63 (In Russ.). doi: 10.14412/1996-7012-2019-1-58-63
37. Dobrovolskaya OV, Demin NV, Smirnov AV, Toroptsova NV. Bone mineral density status and the need for anti-osteoporotic therapy in postmenopausal women with systemic scleroderma. Medical Council. 2019;(9): 72-79 (In Russ.). doi: 10.21518/2079-701X-2019-9-72-79
38. John G. Systemic sclerosis and urinary symptoms: A complex pathophysiology. Clin Rheumatol. 2020;39(1):5-8. doi: 10.1007/ s10067-019-04714-y
39. John G, Avouac J, Piantoni S, Polito P, Fredi M, Cozzi F, et al. Prevalence and disease-specific risk factors for lower urinary tract symptoms in systemic sclerosis: An international multicenter study. Arthritis Care Res (Hoboken). 2018;70(8):1218-1227. doi: 10.1002/ acr.23454
40. Irwin DE, Milsom I, Hunskaar S, Reilly K, Kopp Z, Herschorn S, et al. Population-based survey of urinary incontinence, overactive bladder, and other lower urinary tract symptoms in five countries: Results of the EPIC study. Eur Urol. 2006;50(6):1306-1314. doi: 10.1016/j.eururo.2006.09.019
41. Zigman JS, Yazdany J, Trinidad J, Yazdany T. Scleroderma and pelvic organ prolapse: A multidisciplinary approach to patient care and surgical planning. J Gynecol Surg. 2017;33(5):198-201. doi: 10.1089/gyn.2017.0014
42. John G, Allanore Y, Polito P, Piantoni S, Fredi M, Avouac J, et al. The limited cutaneous form of systemic sclerosis is associated with urinary incontinence: An international multicentre study. Rheumatology (Oxford). 2017;56(11):1874-1883. doi: 10.1093/ rheumatology/kex230
43. Motegi SI, Sekiguchi A, Sekine Y, Nakayama H, Suzuki K, Ishikawa O. Prevalence and clinical characteristics of overactive bladder in systemic sclerosis. Mod Rheumatol. 2020;30(2):327-331. doi: 10.1080/14397595.2019.1589913
44. Kucharz EJ, Jonderko G, Rubisz-Brzezinska J, Końca A, Jarczyk R. Premictional volume and contractility of the urinary bladder in patients with systemic sclerosis. Clin Rheumatol. 1996;15(2):118-120. doi: 10.1007/BF02230326
45. Kondo A, Susset JG. Viscoelastic properties of bladder. II. Comparative studies in normal and pathologic dogs. Invest Urol. 1974;11(6):459-465.
46. Minervini R, Morelli G, Minervini A, Pampaloni S, Tognetti A, Fiorentini L, et al. Bladder involvement in systemic sclerosis: Urodynamic and histological evaluation in 23 patients. Eur Urol. 1998;34(1):47-52. doi: 10.1159/000019678
47. Leinwand I, Duryee AW, Richter MN. Scleroderma; based on a study of over 150 cases. Ann Intern Med. 1954;41(5):1003- 1041. doi: 10.7326/0003-4819-41-5-1003
48. Bertinotti L, Bracci S, Nacci F, Colangelo N, Del Rosso A, Casale R, et al. The autonomic nervous system in systemic sclerosis. A review. Clin Rheumatol. 2004;23(1):1-5. doi: 10.1007/ s10067-003-0812-4
49. Compérat E, Reitz A, Delcourt A, Capron F, Denys P, ChartierKastler E. Histologic features in the urinary bladder wall affected from neurogenic overactivity – A comparison of inflammation, oedema and fibrosis with and without injection of botulinum toxin type A. Eur Urol. 2006;50(5):1058-1064. doi: 10.1016/ j.eururo.2006.01.025
50. Thoua NM, Abdel-Halim M, Forbes A, Denton CP, Emmanuel AV. Fecal incontinence in systemic sclerosis is secondary to neuropathy. Am J Gastroenterol. 2012;107(4):597-603. doi: 10.1038/ ajg.2011.399
51. Singh J, Mehendiratta V, Del Galdo F, Jimenez SA, Cohen S, DiMarino AJ, et al. Immunoglobulins from scleroderma patients inhibit the muscarinic receptor activation in internal anal sphincter smooth muscle cells. Am J Physiol Gastrointest Liver Physiol. 2009;297(6):G1206-G1213. doi: 10.1152/ajpgi.00286.2009
52. Fetscher C, Fleichman M, Schmidt M, Krege S, Michel MC. M(3) muscarinic receptors mediate contraction of human urinary bladder. Br J Pharmacol. 2002;136(5):641-643. doi: 10.1038/ sj.bjp.0704781
53. Lekakis J, Mavrikakis M, Papamichael C, Papazoglou S, Economou O, Scotiniotis I, et al. Short-term estrogen administration improves abnormal endothelial function in women with systemic sclerosis and Raynaud’s phenomenon. Am Heart J. 1998; 136(5):905-912. doi: 10.1016/s0002-8703(98)70137-1
54. Lekakis J, Papamichael C, Mavrikakis M, Voutsas A, Stamatelopoulos S. Effect of long-term estrogen therapy on brachial arterial endothelium-dependent vasodilation in women with Raynaud’s phenomenon secondary to systemic sclerosis. Am J Cardiol. 1998;82(12):1555-1557. doi: 10.1016/ s0002-9149(98)00708-5
55. Haenggi W, Linder HR, Birkhaeuser MH, Schneider H. Microscopic findings of the nail-fold capillaries – dependence on menopausal status and hormone replacement therapy. Maturitas. 1995; 22(1):37-46. doi: 10.1016/0378-5122(95)00911-4
56. Steen V, Medsger TA Jr. Predictors of isolated pulmonary hypertension in patients with systemic sclerosis and limited cutaneous involvement. Arthritis Rheum. 2003;48(2):516-522. doi: 10.1002/ art.10775
57. Beretta L, Caronni M, Origgi L, Ponti A, Santaniello A, Scorza R. Hormone replacement therapy may prevent the development of isolated pulmonary hypertension in patients with systemic sclerosis and limited cutaneous involvement. Scand J Rheumatol. 2006;35(6):468-471. doi: 10.1080/03009740600844498
58. Scorza R, Caronni M, Bazzi S, Nador F, Beretta L, Antonioli R, et al. Post-menopause is the main risk factor for developing isolated pulmonary hypertension in systemic sclerosis. Ann N Y Acad Sci. 2002;966:238-246. doi: 10.1111/j.1749-6632.2002.tb04221.x
59. Maria ATJ, Partouche L, Goulabchand R, Rivière S, Rozier P, Bourgier C, et al. Intriguing relationships between cancer and systemic sclerosis: Role of the immune system and other contributors. Front Immunol. 2019;9:3112. doi: 10.3389/ fimmu.2018.03112
60. Shah AA, Rosen A, Hummers L, Wigley F, Casciola-Rosen L. Close temporal relationship between onset of cancer and scleroderma in patients with RNA polymerase I/III antibodies. Arthritis Rheum. 2010;62(9):2787-2795. doi: 10.1002/art.27549
61. Airo’ P, Ceribelli A, Cavazzana I, Taraborelli M, Zingarelli S, Franceschini F. Malignancies in Italian patients with systemic sclerosis positive for anti-RNA polymerase III antibodies. J Rheumatol. 2011;38(7):1329-1334. doi: 10.3899/jrheum.101144
62. Li CI, Daling JR, Tang MT, Haugen KL, Porter PL, Malone KE. Use of antihypertensive medications and breast cancer risk among women aged 55 to 74 years. JAMA Intern Med. 2013;173(17):1629- 1637. doi: 10.1001/jamainternmed.2013.9071
63. Gómez-Acebo I, Dierssen-Sotos T, Palazuelos C, PérezGómez B, Lope V, Tusquets I, et al. The use of antihypertensive medication and the risk of breast cancer in a case-control study in a Spanish population: The MCC-spain study. PLoS One. 2016;11(8):e0159672. doi: 10.1371/journal.pone.0159672
64. Lu TY, Hill CL, Pontifex EK, Roberts-Thomson PJ. Breast cancer and systemic sclerosis: A clinical description of 21 patients in a population-based cohort study. Rheumatol Int. 2008;28(9): 895-899. doi: 10.1007/s00296-008-0540-9
65. De Angelis R, Di Battista J, Smerilli G, Cipolletta E, Di Carlo M, Salaffi F. Association of silicone breast implants, breast cancer and anti-RNA polymerase III autoantibodies in systemic sclerosis: Case-based review. Open Access Rheumatol. 2020;12:207-213. doi: 10.2147/OARRR.S262428
Review
For citations:
Panevin T.S., Ananyeva L.P. Pathogenetic rationale for prescribing menopausal hormone therapy for systemic sclerosis. Rheumatology Science and Practice. 2022;60(5):538-545. (In Russ.) https://doi.org/10.47360/1995-4484-2022-538-545
Views:
430
Email this article 